Ars Pharmaceuticals Inc (SPRY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
The Schall Law Firm Begins Probe Into Claims Against ARS Pharmaceuticals Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Allegations Against ARS Pharmaceuticals Inc Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Allegations Against ARS Pharmaceuticals Inc The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Claims Against Ars Pharmaceuticals Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charges Against ARS Pharmaceuticals, Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Accusations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Inquiry And Calls On Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Claims Against ARS Pharmaceuticals, Inc.: Schall Law Firm Begins Probe And Invites Affected Investors To Connect
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals, Inc. Allegations: Schall Law Firm Commences Examination and Calls on Affected Investors to Connect
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm is commencing an examination into allegations against ARS Pharmaceuticals, Inc. and is calling on investors who have experienced losses to get in touch
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SPRY INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
